Importantly, the efficacy of BMS-986351 and cetuximab in colorectal cancer cell lines with KRAS mutations represents a potential treatment opportunity for cetuximab-resistant tumors, given that the mechanism of action of BMS-986351 may be independent of EGFR pathway activity. The gene discussed is EGFR; the disease is colorectal cancer.